Caladrius Biosciences, Inc. (LSTA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
August 13, 2024 6:04 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $15.00 price target on Lisata Therapeutics, Inc (NASDAQ: LSTA).
The analyst comments "Financial and corporate update. Yesterday after the close, Lisata announced 2Q24 financial results, posting EPS of ($0.61) compared to our estimate of ($0.76)... More
